Founder and Managing Director

Bryan Brokmeier has over 20 years of capital markets experience, including as an investor relations officer (IRO) and a sell-side analyst. Bryan has built multiple investor relations programs from the ground up, leveraging his deep understanding of institutional investor mindsets and strong relationships that were developed over the course of his career. Bryan’s expertise includes leading ESG programs, engagement with investment stewardship/proxy teams and activists, and managing investor communications during critical events encompassing a public offering, M&A transactions, adverse macro environments, executive turnover, and shareholder activism/contentious proxy votes. 

Most recently, Bryan served as Vice President of Investor Relations for QuidelOrtho Corp, one of the largest pure-play diagnostic tools companies formed by Quidel Corp’s May 2022 acquisition of Ortho Clinical Diagnostics. At QuidelOrtho, Bryan led the development and execution of the company’s investor relations strategy, investor communications, and shareholder engagement, as well as establishment of the company’s environmental, social, and governance program. In his role, he also worked with the communications team, global marketing, and the disclosure committee on the company’s external communications strategy, planning, and disclosures.

Prior to the formation of QuidelOrtho, Bryan served as Vice President of Investor Relations for Ortho Clinical Diagnostics, where he leveraged institutional investor relationships to more than double long-only investor engagement, including a tripling of new investor introductions in the initial months after joining in July 2021. Bryan successfully oversaw investor relations for the company through a successful $443 million secondary offering as well as the 2022 acquisition by Quidel Corp. to form QuidelOrtho. 

Before Ortho, Bryan was Head of Investor Relations at Waters Corp, a leading life science tools company with a primary focus on the pharmaceutical market, where he was responsible for building the first full-time investor relations program for the Company and establishing investor relations as a strategic function. Through targeted engagement Bryan expanded the shareholder base of long-only investors, notably in Boston, Canada, and Europe. As a member of the senior leadership team and a founding member of the competitive strategy team, Bryan worked with the executive committee to analyze the competitive environment, identify opportunities and threats, and align and accelerate efforts to execute the global strategy. In addition, he led Waters’ ESG outreach strategy and co-led sustainability reporting that drove an increase in the S&P CSA score to 83rd percentile, from 31st percentile and an upgrade in the company’s MSCI ESG rating to AAA, from AA, as well as recognition on the Newsweek list of America’s Most Responsible Companies 2021 and Barron’s 2021 list of the 100 Most Sustainable Companies.

Prior to running investor relations programs, Bryan was an equity research analyst with over ten years of experience working at Credit Suisse, Maxim Group, and Cantor Fitzgerald, primarily covering life science tools, diagnostics, and medtech, as well as healthcare IT and healthcare services. Bryan participated in hundreds of earnings calls, wrote close to 1,000 sell-side reports, and had approximately 2,000 calls and meetings with institutional investors. Bryan was consistently ranked in the top quartile in his firm’s institutional sales surveys, one of the top vote earners from the firm’s largest commission paying clients, and was rated the best stock picker in the Life Science Tools and Services category by Thomson Reuters Starmine in 2014.

Mr. Brokmeier earned an MBA from the Kelley School of Business at Indiana University and a B.S. in Finance and Applied Economics from Ithaca College. He is a CFA Charterholder and a member of the CFA Institute and the New York Society of Security Analysts.